building towards their Inaugural Investors Day June 18 where they are expected to release data from Zydax (pentosan polysulphate) phase III for canine osteoarthritis.
I'm thinking ZYDAX (fascimile} will find it's way into human trials eventually, I see no reason why not, the human joint is a larger easier target and we 'STAY' (hold still) better. ;)